http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101390625-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4706 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P13-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P13-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2007-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101390625-B1 |
| titleOfInvention | Compositions and methods for the prediction of cardiac toxicity and reduction of cell fat upon treatment with tyrosine kinase inhibitors |
| abstract | Disclosed are methods for determining whether long term toxicity, in particular cardiac toxicity, will occur in a patient selected for treatment with various kinase inhibitors, for example tyrosine kinase inhibitors, more particularly erbB inhibitors such as herceptin. Also disclosed are methods for determining whether a potential drug is likely to produce a cardiotoxic effect. The method includes analyzing lipid levels or expressing fatty acid oxidase, pAMP activated protein kinase, glucose uptake to determine whether a fatty acid oxidation disorder is present. The identification of fatty acid oxidation disorders can be used as predictors of toxicity, especially cardiac toxicity, and as an indicator where long-term function should be carefully monitored when administering drugs such as tyrosine kinase inhibitors. Also disclosed are methods of protecting organs from metabolic stress and treating cells such as adipocytes to reduce lipid content.n n n Tyrosine kinase inhibitors, organ toxicity, cardiac toxicity, fatty acid oxidation disorders |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210096770-A |
| priorityDate | 2006-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1628.